Compare AMZE & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMZE | SNGX |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.6M |
| IPO Year | N/A | 2006 |
| Metric | AMZE | SNGX |
|---|---|---|
| Price | $0.12 | $0.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 3.9M | 814.2K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | $1,986.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.28 |
| 52 Week High | $11.70 | $6.23 |
| Indicator | AMZE | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 39.23 |
| Support Level | $0.12 | $0.37 |
| Resistance Level | $0.20 | $0.41 |
| Average True Range (ATR) | 0.01 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 16.80 | 14.65 |
Amaze Holdings Inc is a technology-enabled, creator-powered commerce platform that enables creators, brands, and consumers to transact at scale. The Company provides infrastructure for creators and brands to design, launch, market, and fulfill products. The Company operates in two segments: E-commerce / Subscriptions, which includes the Amaze platform and creator commerce operations supporting product sales, subscription offerings, and digital content delivery; and Wine Products, which includes the sale of Fresh Vine wines through wholesale and direct-to-consumer channels across the United States and Puerto Rico.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).